COVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical,
and management outcome features of COVID-19 patients have been defined rapidly, the …

Background and Objectives To evaluate the immune-specific response after full severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with multiple …

SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease. The
pathogenesis of severe cases remains unknown. We performed an in-depth prospective …

Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly
developed to help restore the massive health and economic disruption caused by the …

SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum
of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to …

Background Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited.
Aim of the study was to investigate immunogenicity according to current CD4 T-cell count …

Introduction Several recent case reports have described common early chest imaging findings
of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be …

Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a
consequence of waning immunity. Serum antibodies represent the most measurable outcome of …

Background An unprecedented global monkeypox outbreak started in May, 2022. No data
are yet available about the dynamics of the immune response against monkeypox virus. The …

Several subsets of αβ regulatory T cells (Tregs) have been described and studied intensively,
but the potential regulatory role of γδ T cells remains largely unclear. Lymphocytes …